Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 104076
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104076
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104076
Figure 3 METTL3-mediated N6-methyladenosine modification of noncoding RNAs in colorectal cancer.
METTL3 participates in colorectal cancer (CRC) by regulating N6-methyladenosine modification of noncoding RNAs (ncRNAs) involved in proliferation, invasion and metastasis, metabolic disorder, and resistance of CRC cells. Each ncRNA was detailed with a name. ncRNAs: Noncoding RNAs; m6A: N6-methyladenosine; CRC: Colorectal cancer.
- Citation: Liao JN, Ni WJ, Wu PH, Yang YD, Yang Y, Long W, Xie MZ, Zhu XZ, Xie FH, Leng XM. Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target. World J Gastrointest Oncol 2025; 17(5): 104076
- URL: https://www.wjgnet.com/1948-5204/full/v17/i5/104076.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.104076